Obigen Pharma Inc. (TPEX:7876)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
37.15
+0.05 (0.13%)
At close: Feb 11, 2026
Market Cap3.97B
Revenuen/a
Net Income-274.31M
EPS-2.59
Shares Out106.92M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume32,700
Average Volume154,604
Open36.70
Previous Close37.10
Day's Range36.55 - 37.15
52-Week Range34.55 - 69.00
Betan/a
RSI46.53
Earnings Daten/a

About Obigen Pharma

Obigen Pharma Inc. engages in research, manufacturing, and promotion of biotechnology and novel botulinum toxin. Preparations in Taiwan. Its lead product OBI-858, a 760 kDa novel toxin protein which fermented and purified from clostridium botulinum type A bacteria, which is in Phase II clinical trial. The company was founded in 2020 and is based in Zhubei, Taiwan. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2020
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 7876
Full Company Profile